Table 4.

ApoE phenotype determined by mass spectrometry

Diagnosis	APOE ε2/ε3 (n)	APOE ε2/ε4 (n)	APOE ε3/ε3 (n)	APOE ε3/ε4 (n)	APOE ε4/ε4 (n)
Whole cohort (n = 125)	5	3	40	47	30
Controls (n = 39)	2	2	21	14	0
MCI-MCI (n = 30)	3	1	8	7	11
MCI-ADD (n = 28)	0	0	7	10	11
ADD (n = 28)	0	0	4	16	8

MCI-MCI patients with amnestic mild cognitive impairment that did not progress to an ADD diagnosis, MCI-ADD patients with mild cognitive impairment that progressed to ADD diagnosis after two years, ADD Alzheimer’s disease with dementia patients diagnosed at baseline, APOE Apolipoprotein E gene